Literature DB >> 1427885

Evidence for the localization of a malignant hyperthermia susceptibility locus (MHS2) to human chromosome 17q.

R C Levitt1, A Olckers, S Meyers, J E Fletcher, H Rosenberg, H Isaacs, D A Meyers.   

Abstract

Malignant hyperthermia susceptibility is a lethal autosomal dominant disorder of skeletal muscle metabolism that is triggered by all potent inhalation anesthetic gases. Recent linkage studies suggest a genetic locus for this disorder on 19q13.1. We have previously reported three unrelated families diagnosed with MHS that are unlinked to markers surrounding this locus on 19q13.1. In this report we extend these observations and present linkage studies on 16 MHS families. Four families (25%) were found linked to the region 19q12-q13.2 (Zmax = 2.96 with the ryanodine receptor at theta = 0.0). Five families (31%) were found closely linked to the anonymous marker NME1 (previously designated NM23) on chromosome 17q11.2-q24 (Zmax = 3.26 at theta = 0.0). Two families (13%) were clearly unlinked to either of these chromosomal regions. In five additional families, data were insufficient to determine their linkage status (they were potentially linked to two or more sites). The results of our heterogeneity analyses are consistent with the hypothesis that MHS can be caused in humans by any one of at least three distinct genetic loci. Furthermore, we provide preliminary linkage data suggesting the localization of a gene in human MHS to 17q11.2-q24 (MHS2), with a gene frequency of this putative locus approximately equal to that of the MHS1 locus on 19q.

Entities:  

Mesh:

Year:  1992        PMID: 1427885     DOI: 10.1016/s0888-7543(05)80152-1

Source DB:  PubMed          Journal:  Genomics        ISSN: 0888-7543            Impact factor:   5.736


  18 in total

1.  Detection of a novel mutation in the ryanodine receptor gene in an Irish malignant hyperthermia pedigree: correlation of the IVCT response with the affected and unaffected haplotypes.

Authors:  K E Keating; L Giblin; P J Lynch; K A Quane; M Lehane; J J Heffron; T V McCarthy
Journal:  J Med Genet       Date:  1997-04       Impact factor: 6.318

2.  Identification and functional characterization of malignant hyperthermia mutation T1354S in the outer pore of the Cavalpha1S-subunit.

Authors:  Antonella Pirone; Johann Schredelseker; Petronel Tuluc; Elvira Gravino; Giuliana Fortunato; Bernhard E Flucher; Antonella Carsana; Francesco Salvatore; Manfred Grabner
Journal:  Am J Physiol Cell Physiol       Date:  2010-09-22       Impact factor: 4.249

Review 3.  Muscle channelopathies and critical points in functional and genetic studies.

Authors:  Karin Jurkat-Rott; Frank Lehmann-Horn
Journal:  J Clin Invest       Date:  2005-08       Impact factor: 14.808

4.  Exome sequencing reveals novel rare variants in the ryanodine receptor and calcium channel genes in malignant hyperthermia families.

Authors:  Jerry H Kim; Gail P Jarvik; Brian L Browning; Ramakrishnan Rajagopalan; Adam S Gordon; Mark J Rieder; Peggy D Robertson; Deborah A Nickerson; Nickla A Fisher; Philip M Hopkins
Journal:  Anesthesiology       Date:  2013-11       Impact factor: 7.892

5.  The G1021A substitution in the RYR1 gene does not cosegregate with malignant hyperthermia susceptibility in a British pedigree.

Authors:  A M Adeokun; S P West; F R Ellis; P J Halsall; P M Hopkins; A M Foroughmand; D E Iles; R L Robinson; A D Stewart; J L Curran
Journal:  Am J Hum Genet       Date:  1997-04       Impact factor: 11.025

6.  Malignant-hyperthermia susceptibility is associated with a mutation of the alpha 1-subunit of the human dihydropyridine-sensitive L-type voltage-dependent calcium-channel receptor in skeletal muscle.

Authors:  N Monnier; V Procaccio; P Stieglitz; J Lunardi
Journal:  Am J Hum Genet       Date:  1997-06       Impact factor: 11.025

7.  Ryanodine receptor gene point mutation and malignant hyperthermia susceptibility.

Authors:  I Moroni; E F Gonano; G P Comi; V Tegazzin; A Prelle; A Bordoni; N Bresolin; G Scarlato
Journal:  J Neurol       Date:  1995-02       Impact factor: 4.849

8.  Diagnosis of malignant hyperthermia: a comparison of the in vitro contracture test with the molecular genetic diagnosis in a large pedigree.

Authors:  J M Healy; K A Quane; K E Keating; M Lehane; J J Heffron; T V McCarthy
Journal:  J Med Genet       Date:  1996-01       Impact factor: 6.318

9.  Screening for mutations in the RYR1 gene in families with malignant hyperthermia.

Authors:  Viviane P Muniz; Helga C A Silva; Ana Maria C Tsanaclis; Mariz Vainzof
Journal:  J Mol Neurosci       Date:  2003       Impact factor: 3.444

10.  The role of CACNA1S in predisposition to malignant hyperthermia.

Authors:  Danielle Carpenter; Christopher Ringrose; Vincenzo Leo; Andrew Morris; Rachel L Robinson; P Jane Halsall; Philip M Hopkins; Marie-Anne Shaw
Journal:  BMC Med Genet       Date:  2009-10-13       Impact factor: 2.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.